Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease

Journal of Virology

Volumn 74, Issue 10, 2000, Pages 4710-4720

  Lin, Ying Chuan ^a   Beck, Zachary ^a   Lee, Taekyu ^a   Le, Van Duc ^a   Morris, Garrett M ^a   Olson, Arthur J ^a   Wong, Chi Huey ^a   Elder, John H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCAMINE; GAG PROTEIN; INTEGRASE; NUCLEOCAPSID PROTEIN; POL PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; SYNTHETIC PEPTIDE;

AMINO ACID SEQUENCE; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITOR INTERACTION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; FELINE IMMUNODEFICIENCY VIRUS; HYDROPHOBICITY; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ASPARTIC ENDOPEPTIDASES; CATS; FLUORESCENT DYES; HIV PROTEASE; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; IMMUNODEFICIENCY VIRUS, FELINE; INHIBITORY CONCENTRATION 50; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS; PEPTIDE LIBRARY; PEPTIDES; PROTEASE INHIBITORS; RETROVIRIDAE PROTEINS; SUBSTRATE SPECIFICITY;

EID: 0033998380     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.10.4710-4720.2000     Document Type: Article

References (49)

1. Aiyar, A., and J. Leis. 1993. Modification of the megaprimer method of PCR mutagenesis: improved amplification of the final product. Biotechniques 14: 366-369.
2. Alewood, P., D. Alewood, L. Miranda, S. Love, W. Meulermans, and D. Wilson. 1997. Rapid in situ neutralization protocols for Boc and Fmoc solid phase chemistries. Methods Enzymol. 289:14-29.
3. Cameron, C. E., T. W. Ridky, S. Shulenin, J. Leis, I. T. Weber, T. Copeland, A. Wlodawer, H. Burstein, D. Bizub-Bender, and A. M. Skalka. 1994. Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases. J. Biol. Chem. 269:11170-11177.
4. Dominy, B. N., and C. L. Brooks 3rd. 1999. Methodology for protein-ligand binding studies: application to a model for drug resistance, the HIV/FIV protease system. Proteins 36:318-331.
5. Dunn, B. M., M. W. Pennington, D. C. Frase, and K. Nash. 1999. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem. Biopolymers 51:69-77.
6. Elder, J. H., G. A. Dean, E. A. Hoover, J. A. Hoxie, M. H. Malim, L. Mathes, J. C. Neil, T. W. North, E. Sparger, M. B. Tompkins, W. A. Tompkins, J. Yamamoto, N. Yuhki, N. C. Pedersen, and R. H. Miller. 1998. Lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses. 14:797-801.
7. Elder, J. H., and T. R. Phillips. 1995. Feline immunodeficiency virus as a model for development of molecular approaches to intervention strategies against lentivirus infections. Adv. Virus Res. 45:225-247.
8. Elder, J. H., M. Schnolzer, C. S. Hasselkus-Light, M. Henson, D. A. Lerner, T. R. Phillips, P. C. Wagaman, and S. B. Kent. 1993. Identification of proteolytic processing sites within the Gag and Pol polyproteins of feline immunodeficiency virus. J. Virol. 67:1869-1876.
9. Fitzgerald, M. C., G. S. Laco, J. H. Elder, and S. B. Kent. 1997. A continuous fluorometric assay for the feline immunodeficiency virus protease. Anal. Biochem. 254:226-230.
10. Flexner, C. 1998. HIV-protease inhibitors. N. Engl. J. Med. 338:1281-1292.
11. Grinde, B., C. E. Cameron, J. Leis, I. T. Weber, A. Wlodawer, H. Burstein, D. Bizub, and A. M. Skalka. 1992. Mutations that alter the activity of the Rous sarcoma virus protease. J. Biol. Chem. 267:9481-9490.
12. Grinde, B., C. E. Cameron, J. Leis, I. T. Weber, A. Wlodawer, H. Burstein, and A. M. Skalka. 1992. Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates. J. Biol. Chem. 267:9491-9498.
13. Gustchina, A. 1995. Molecular modeling of the structure of FIV protease. Adv. Exp. Med. Biol. 362:479-484.
14. Henderson, P. J. F. 1972. A linear equation that describes the steady state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors. Biochem. J. 127:321-333.
15. Hoog, S. S., E. M. Towler, B. Zhao, M. L. Doyle, C. Debouck, and S. S. Abdel-Meguid. 1996. Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity. Biochemistry 35: 10279-10286.
16. Katz, R. A., and A. M. Skalka. 1994. The retroviral enzymes. Annu. Rev. Biochem. 63:133-173.
17. Kempf, D. J., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fino, C. H. Park, and X. P. Kong. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92: 2484-2488.
18. Krohn, A., S. Redshaw, J. C. Ritchie, B. J. Graves, and M. H. Hatada. 1991. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J. Med. Chem. 34:3340-3342.
19. Laco, G. S., M. C. Fitzgerald, G. M. Morris, A. J. Olson, S. B. Kent, and J. H. Elder. 1997. Molecular analysis of the feline immunodeficiency virus protease: generation of a novel form of the protease by autoproteolysis and construction of cleavage-resistant proteases. J. Virol. 71:5505-5511.
20. Laco, G. S., C. Schalk-Hihi, J. Lubkowski, G. Morris, A. Zdanov, A. Olson, J. H. Elder, A. Wlodawer, and A. Gustchina. 1997. Crystal structures of the inactive D30N mutant of feline immunodeficiency virus protease complexed with a substrate and an inhibitor. Biochemistry 36:10696-10708.
21. Lee, T., G. S. Laco, B. E. Torbett, H. S. Fox, D. L. Lerner, J. H. Elder, and C. H. Wong. 1998. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo. Proc. Natl. Acad. Sci. USA 95:939-944.
22. Lee, T., V. D. Le, D. Lim, Y. C. Lin, G. M. Morris, A. L. Wong, A. J. Oison, J. E. Elder, and C. H. Wong. 1999. Development of a new type of protease inhibitors, efficacious against FIV and HIV variants. J. Am. Chem. Soc. 121: 1145-1155.
23. Li, M., G. M. Morris, T. Lee, G. S. Laco, C.-H. Wong, A. J. Olson, J. H. Elder, A. Wlodawer, and A. Gustchina. 2000. Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FlV protease. Proteins Struct. Funct. Genet. 38:29-40.
24. Loeb, D. D., R. Swanstrom, L. Everitt, M. Manchester, S. E. Stamper, and C. A. D. Hutchison. 1989. Complete mutagenesis of the HIV-1 protease. Nature 340:397-400.
25. Matayoshi, E. D., G. T. Wang, G. A. Kraft, and J. Erickson. 1990. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science 247:954-958.
26. Mcdonald, C. K., and D. R. Kuritzkes. 1997. Human immunodeficiency virus type 1 protease inhibitors. Arch. Intern. Med. 157:951-959.
27. Pettit, S. C., N. Sheng, R. Tritch, S. Erickson-Viitanen, and R. Swanstrom. 1998. The regulation of sequential processing of HIV-1 Gag by the viral protease. Adv. Exp. Med. Biol. 436:15-25.
28. Poorman, R. A., A. G. Tomasselli, R. L. Heinrikson, and F. J. Kezdy. 1991. A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base. J. Biol. Chem. 266:14554-14561.
29. Powell, D. J., D. Bur, A. Wlodawer, A. Gustchina, S. L. Payne, B. M. Dunn, and J. Kay. 1996. Expression, characterisation and mutagenesis of the aspartic proteinase from equine infectious anaemia virus. Eur. J. Biochem. 241:664-674. (Erratum, 246:258, 1997.)
30. Richards, A. D., L. H. Phylip, W. G. Farmerie, P. E. Scarborough, A. Alvarez, B. M. Dunn, P. H. Hirel, J. Konvalinka, P. Strop, L. Pavlickova, et al. 1990. Sensitive, soluble chromogenic substrates for HIV-1 proteinase. J. Biol. Chem. 265:7733-7736.
31. Ridky, T. W., D. Bizub-Bender, C. E. Cameron, I. T. Weber, A. Wlodawer, T. Copeland, A. M. Skalka, and J. Leis, 1996. Programming the Rous sarcoma virus protease to cleave new substrate sequences. J. Biol. Chem. 271:10538-10544.
32. Ridky, T. W., A. Kikonyogo, J. Leis, S. Gulnik, T. Copeland, J. Erickson, A. Wlodawer, I. Kurinov, R. W. Harrison, and I. T. Weber. 1998. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. Biochemistry 37:13835-13845.
33. Sarkar, G., and S. S. Sommer. 1990. The "megaprimer" method of site-directed mutagenesis. Biotechniques 8:404-407.
34. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 1997. Mutations in retroviral genes associated with drug resistance. Int. Antiviral News 5:129-142.
35. Schnolzer, M., H. R. Rackwitz, A. Gustchina, G. S. Laco, A. Wlodawer, J. H. Elder, and S. B. Kent. 1996. Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis. Virology 224:268-275.
36. Shao, W., L. Everitt, M. Manchester, D. D. Loeb, C. A. Hutchison 3rd, and R. Swanstrom. 1997. Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants. Proc. Natl. Acad. Sci. USA 94:2243-2248.
37. Slee, D. H., K. L. Laslo, J. H. Elder, I. R. Ollmann, A. Gustchina, K. Kervinen, A. Zdanov, A. Wlodawer, and C.-H. Wong. 1995. Selectivity in the inhibition of HIV and FIV protease: inhibitory and mechanistic studies of pyrolidine-containing a-keto amide and core structures. J. Am. Chem. Soc. 117:11867-11878.
38. Stebbins, J., E. M. Towler, M. G. Tennant, I. C. Deckman, and C. Debouck. 1997. The 80's loop (residues 78 to 85) is important for the differential activity of retroviral proteases. J. Mol. Biol. 267:467-475.
39. Studier, F. W., and B. A. Moffatt. 1986. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol. 189:113-130.
40. Tomasselli, A. G., and R. L. Heinrikson. 1994. Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates. Methods Enzymol. 241:279-301.
41. Toth, M. V., and G. R. Marshall. 1990. A simple, continuous fluorometric assay for HIV protease. Int. J. Peptide Protein Res. 36:544-550.
42. Towler, E. M., S. K. Thompson, T. Tomaszek, and C. Debouck. 1997. Identification of a loop outside the active site cavity of the human immunodeficiency virus proteases which confers inhibitor specificity. Biochemistry 36: 5128-5133.
43. Tozser, J., I. Blaha, T. D. Copeland, E. M. Wondrak, and S. Oroszlan. 1991. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Lett. 281:77-80.
44. Udenfriend, S., S. Stein, P. Bohlen, W. Dairman, W. Leimgruber, and M. Weigele. 1972. Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science 178:871-872.
45. Vacca, J. P., and J. H. Condra. 1997. Clinically effective HIV-1 protease inhibitors. Drug Discovery 2:261-272.
46. von der Helm, K. 1996. Retroviral proteases: structure, function and inhibition from a nonanticipated viral enzyme to the target of a most promising HIV therapy. Biol. Chem. 377:765-774.
47. Wallqvist, A., G. W. Smythers, and D. G. Covell. 1998. A cooperative folding unit in HIV-1 protease. Implications for protein stability and occurrence of drug-induced mutations. Protein Eng. 11:999-1005.
48. Wang, G. T., E. Matayoshi, H. J. Huffaker, and G. A. Kraft. 1990. Design and synthesis of new fluorogenic HIV protease substrates based on resonance energy transfer. Tetrahedron Lett. 31:6493-6496.
49. Wlodawer, A., A. Gustchina, L. Reshetnikova, J. Lubkowski, A. Zdanov, K. Y. Hui, E. L. Angleton, W. G. Farmerie, M. M. Goodenow, D. Bhatt, et al. 1995. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus. Nat. Struct. Biol. 2:480-488.